ICU Medical (ICUI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$172.62+6.67%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · ICUI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.9% |
| Our one-year growth estimate | diamond | 4.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to the broad stock market and long-term interest rates.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 0.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 11 industry peers
ICUI — officer change
Dated 2026-02-20
The filing pertains to an amendment of the Executive Severance Plan, which is a routine administrative matter.
Why it matters: The company raised its 2026 adjusted EBITDA range to $415 million to $435 million. Meeting the low end would support that higher outlook.
Supportive ifFull-year 2026 adjusted EBITDA is at least $415 million.
Worry ifFull-year 2026 adjusted EBITDA is below $415 million. Or, the company cuts its range below that level.
Why it matters: Q2 adjusted EPS was $2.37, up from $2.10 a year ago. A higher Q3 result would extend that gain.
Supportive ifOn November 5, Q3 adjusted EPS is above $2.37.
Worry ifOn November 5, Q3 adjusted EPS is $2.10 or lower.
Why it matters: First-half operating cash flow was $119.1 million, up from $62.5 million a year ago. More cash in the second half would extend that gain.
Supportive ifNet cash from operating activities is above $62.5 million in the second half of 2026.
Worry ifNet cash from operating activities is $62.5 million or less in the second half of 2026.
Why it matters: The company lists the timing and outcome of the warning letter as a risk. A clear resolution would reduce uncertainty; an open or delayed matter would not.
Watch forThe company says it resolved the 2025 warning letter, with no open actions noted.
Also watch forThe company says the warning letter is still unresolved, or reports more delays or new actions.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$135 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $314 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,718 loss on $10,000 · 27.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Gross margin rose from 39% in Q1 to 43% in Q2. Another result above 40% would extend the recent gains.
Supportive ifQ3 GAAP gross margin is above 40%.
Worry ifQ3 GAAP gross margin is 39% or lower.
Why it matters: Organic revenue rose 1% in Q1 and 6% in Q2, excluding the sale of IV Solutions and currency. Growth above 1% would keep that trend intact.
Supportive ifQ3 non-GAAP organic revenue growth is above 1% year over year. This excludes IV Solutions and currency.
Worry ifQ3 non-GAAP organic revenue growth is zero or negative. This excludes IV Solutions and currency.